相似文献
1
Points to consider when doing a trial primarily involving the heart.
Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v12-v16. doi: 10.1093/rheumatology/kex198.
2
[Cardiopathy in systemic sclerosis].
Recenti Prog Med. 1996 Nov;87(11):557-63.
3
Systemic sclerosis and the heart.
Rheum Dis Clin North Am. 2014 Feb;40(1):87-102. doi: 10.1016/j.rdc.2013.10.007. Epub 2013 Nov 7.
4
Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis.
Rheumatology (Oxford). 2020 Sep 1;59(9):2523-2533. doi: 10.1093/rheumatology/kez658.
5
Unique Abnormalities in Right Ventricular Longitudinal Strain in Systemic Sclerosis Patients.
Circ Cardiovasc Imaging. 2016 Jun;9(6). doi: 10.1161/CIRCIMAGING.115.003792. Epub 2016 Jun 7.
6
Ventricular late potentials in systemic sclerosis: relationship with skin involvement.
J Rheumatol. 2002 Jul;29(7):1388-92.
7
Heart disease in systemic sclerosis.
Semin Arthritis Rheum. 1989 Dec;19(3):191-200. doi: 10.1016/0049-0172(89)90032-2.
8
[Heart involvement in systemic sclerosis: analysis of four cases].
Ann Acad Med Stetin. 2012;58(1):33-9; discussion 39.
9
Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis.
Rheumatology (Oxford). 2017 Jun 1;56(6):912-921. doi: 10.1093/rheumatology/kew488.
10
Primary myocardial disease in scleroderma-a comprehensive review of the literature to inform the UK Systemic Sclerosis Study Group cardiac working group.
Rheumatology (Oxford). 2017 Jun 1;56(6):882-895. doi: 10.1093/rheumatology/kew364.
引用本文的文献
1
Assessment of myocardial fibrosis in patients with systemic sclerosis using [Ga]Ga-FAPI-04-PET-CT.
Eur J Nucl Med Mol Imaging. 2023 May;50(6):1629-1635. doi: 10.1007/s00259-022-06081-4. Epub 2022 Dec 16.
2
Systemic sclerosis: state of the art on clinical practice guidelines.
RMD Open. 2018 Oct 18;4(Suppl 1):e000782. doi: 10.1136/rmdopen-2018-000782. eCollection 2018.
本文引用的文献
1
Interstitial lung disease points to consider for clinical trials in systemic sclerosis.
Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v27-v32. doi: 10.1093/rheumatology/kex203.
2
Points to consider in renal involvement in systemic sclerosis.
Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v49-v52. doi: 10.1093/rheumatology/kex201.
3
Muscle involvement in systemic sclerosis: points to consider in clinical trials.
Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v38-v44. doi: 10.1093/rheumatology/kex196.
4
Cardiac biomarkers in systemic sclerosis: contribution of high-sensitivity cardiac troponin in addition to N-terminal pro-brain natriuretic peptide.
Arthritis Care Res (Hoboken). 2015 Jul;67(7):1022-30. doi: 10.1002/acr.22547.
5
Cardiac arrhythmias and conduction defects in systemic sclerosis.
Rheumatology (Oxford). 2014 Jul;53(7):1172-7. doi: 10.1093/rheumatology/ket377. Epub 2013 Nov 15.
6
The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review.
J Rheumatol. 2013 Sep;40(9):1545-56. doi: 10.3899/jrheum.121380. Epub 2013 Jul 15.
7
Early assessment of sub-clinical cardiac involvement in systemic sclerosis (SSc) using delayed enhancement cardiac magnetic resonance (CE-MRI).
Eur J Radiol. 2013 Jun;82(6):e268-73. doi: 10.1016/j.ejrad.2013.02.014. Epub 2013 Mar 16.
8
Six-minute walk distance as a marker for disability and complaints in patients with systemic sclerosis.
Clin Exp Rheumatol. 2011 Mar-Apr;29(2 Suppl 65):S53-9. Epub 2011 May 13.
9
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database.
Ann Rheum Dis. 2010 Oct;69(10):1809-15. doi: 10.1136/ard.2009.114264. Epub 2010 Jun 15.
10
Lack of specificity of the 6-minute walk test as an outcome measure for patients with systemic sclerosis.
J Rheumatol. 2009 Jul;36(7):1481-5. doi: 10.3899/jrheum.081221. Epub 2009 Jun 1.
Zotero 插件